Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

Fabio Y. Moraes, Luke A. Perry, Jahan C. Penny-Dimri, Dhruvesh Ramson, Tiago B. de Castria, Rayleen V. Bowman, Fábio N. Santos, Kwun M. Fong, Rachel Riera

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).

Original languageEnglish
Article numberCD012644
Number of pages14
JournalCochrane Database of Systematic Reviews
Volume2017
Issue number4
DOIs
Publication statusPublished - 26 Apr 2017

Cite this